CLRB

Cellectar Biosciences, Inc. [CLRB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CLRB Stock Summary

Top 10 Correlated ETFs

CLRB


Top 10 Correlated Stocks

CLRB


In the News

01:32 24 Mar 2023 CLRB

Here's Why Cellectar Biosciences Shares Are Rising

Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earnings by 10.0%, reporting an EPS loss of 9 cents versus an estimate of a.

07:46 24 Mar 2023 CLRB

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

10:52 24 Mar 2023 CLRB

Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week

5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

07:32 24 Mar 2023 CLRB

Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed John Friend MD, the former chief medical officer (CMO) at Cellectar Biosciences (NASDAQ:CLRB), Inc as its new CMO.  Dr Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and collaborate with clinicians and scientists to advance the company's research programs.

12:27 24 Mar 2023 CLRB

Cellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer

Cellectar Biosciences Inc (NASDAQ: CLRB) has completed part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination with external beam radiation (EBRT) in relapsed or refractory head and neck cancer.  Related: Cellectar Receives $2M NIH Grant For Rare Lymphoma Study.

04:01 24 Mar 2023 CLRB

Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview at the following upcoming conference:

11:54 24 Mar 2023 CLRB

Cellectar Receives $2M NIH Grant For Rare Lymphoma Study

Cellectar Biosciences Inc (NASDAQ: CLRB) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the National Cancer Institute (NCI). The Company is currently conducting a pivotal study of iopofosine I-131 (CLR 131) in Waldenstrom's macroglobulinemia (WM) patients who have received at least two prior lines of therapy.

08:30 24 Mar 2023 CLRB

Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia

FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 Million from the National Cancer Institute (NCI).

08:30 24 Mar 2023 CLRB

Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131

Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 131)

08:30 24 Mar 2023 CLRB

Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update

FLORHAM PARK, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

CLRB Financial details

Company Rating
Neutral
Market Cap
14.81M
Income
-28.6M
Revenue
0
Book val./share
2.2
Cash/share
2.82
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
08 May 2023
P/E
-0.34
Forward P/E
-
PEG
-0.66
P/S
-
P/B
0.74
P/C
0.55
P/FCF
-0.66
Quick Ratio
2.73
Current Ratio
2.88
Debt / Equity
0.39
LT Debt / Equity
0.04
-
-
EPS (TTM)
-4.52
EPS next Y
-
EPS next Q
-
EPS this Y
-5.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20.31%
-
-
-
-
SMA20
-4.94%
SMA50
-10.47%
SMA100
-23.38%
Inst Own
30.79%
Inst Trans
-69.21%
ROA
-141%
ROE
-117%
ROC
-2.13%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
9.74M
Shs Float
6.7M
-
-
-
-
Target Price
-
52W Range
1.25-7.9
52W High
-78%
52W Low
+54%
RSI
44.29
Rel Volume
0.14
Avg Volume
71.32K
Volume
9.64K
Perf Week
-2.53%
Perf Month
-11.19%
Perf Quarter
-54.17%
Perf Half Y
-65.85%
-
-
-
-
Beta
1.17152
-
-
Volatility
0.02%, 0.13%
Prev Close
2.33%
Price
1.54
Change
-1.28%

CLRB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-44.7-18.36-7.62-4.35-4.05
Operating cash flow per share
-38.63-15.24-7.03-4.070
Free cash flow per share
-39.93-15.27-7.06-4.09-0.03
Cash per share
44.7513.8328.856.432.82
Book value per share
44.7711.827.665.952.2
Tangible book value per share
44.7711.827.665.952.2
Share holders equity per share
44.7711.827.665.952.2
Interest debt per share
0.110.740.220.050.09
Market cap
4.59M17.27M41.21M36.86M12.07M
Enterprise value
-8.66M7.18M-15.53M1.46M-7.2M
P/E ratio
-0.35-1.23-2.73-1.53-0.42
Price to sales ratio
00000
POCF ratio
-0.4-1.48-2.96-1.630
PFCF ratio
-0.39-1.47-2.94-1.62-53.39
P/B Ratio
0.351.910.751.120.78
PTB ratio
0.351.910.751.120.78
EV to sales
00000
Enterprise value over EBITDA
0.66-0.521.04-0.060.25
EV to operating cash flow
0.76-0.611.11-0.060
EV to free cash flow
0.73-0.611.11-0.0631.85
Earnings yield
-2.88-0.82-0.37-0.65-2.37
Free cash flow yield
-2.58-0.68-0.34-0.62-0.02
Debt to equity
0.140.350.070.130.39
Debt to assets
0.120.260.070.110.28
Net debt to EBITDA
1.010.723.81.480.68
Current ratio
8.64.1116.269.163.71
Interest coverage
-392.61-331.96-1.4K-10.57K0
Income quality
0.860.830.920.940
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.03000.010
Capex to revenue
00000
Capex to depreciation
-4.68-0.18-0.44-0.94-1.52
Stock based compensation to revenue
00000
Graham number
212.1969.8368.8524.1214.16
ROIC
0.971.380.270.681.58
Return on tangible assets
-0.88-1.15-0.26-0.65-1.32
Graham Net
38.79.6726.95.681.95
Working capital
12.33M8.62M54.38M32.58M15M
Tangible asset value
13.26M9.06M54.79M33.05M15.51M
Net current asset value
12.16M8.19M54.07M32.41M14.45M
Invested capital
00.060.010.010.04
Average receivables
00000
Average payables
306K945K1.35M1.42M707.5K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1-1.56-0.28-0.73-1.84
Capex per share
-1.3-0.03-0.03-0.03-0.03

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
Revenue per share
00000
Net income per share
-0.99-1-1.22-1.28-1.02
Operating cash flow per share
-0.75-0.82-0.94-1.150
Free cash flow per share
-0.78-0.83-0.95-1.152.51
Cash per share
5.965.014.062.912.82
Book value per share
5.524.453.312.092.2
Tangible book value per share
5.524.453.312.092.2
Share holders equity per share
5.524.453.312.092.2
Interest debt per share
0.050.040.040.030.09
Market cap
39.75M42.03M24.67M20.53M12.07M
Enterprise value
4.35M11.66M103.17K2.95M-7.2M
P/E ratio
-1.68-1.71-0.83-0.66-0.42
Price to sales ratio
00000
POCF ratio
-8.81-8.34-4.29-2.930
PFCF ratio
-8.57-8.29-4.23-2.920.68
P/B Ratio
1.21.541.221.610.78
PTB ratio
1.21.541.221.610.78
EV to sales
00000
Enterprise value over EBITDA
-0.74-1.91-0.01-0.380.99
EV to operating cash flow
-0.96-2.31-0.02-0.420
EV to free cash flow
-0.94-2.3-0.02-0.42-0.41
Earnings yield
-0.15-0.15-0.3-0.38-0.6
Free cash flow yield
-0.12-0.12-0.24-0.341.47
Debt to equity
0.130.180.280.520.39
Debt to assets
0.110.150.220.340.28
Net debt to EBITDA
6.024.983.322.262.66
Current ratio
9.166.754.512.883.71
Interest coverage
4.46K-14.28K-15.46K-1.88K0
Income quality
0.760.820.770.90
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.030.010.0100
Capex to revenue
00000
Capex to depreciation
-3.3-0.69-2.09-0.21-3.09
Stock based compensation to revenue
00000
Graham number
11.0810.039.517.757.11
ROIC
0.170.210.310.480.41
Return on tangible assets
-0.16-0.19-0.29-0.4-0.33
Graham Net
5.274.233.131.841.95
Working capital
32.58M26.74M19.68M12.25M15M
Tangible asset value
33.05M27.21M20.19M12.75M15.51M
Net current asset value
32.41M26.61M19.59M12.19M14.45M
Invested capital
0.010.010.010.020.04
Average receivables
00000
Average payables
707.5K707.5K000
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.18-0.23-0.37-0.61-0.47
Capex per share
-0.020-0.010-0.02

CLRB Frequently Asked Questions

What is Cellectar Biosciences, Inc. stock symbol ?

Cellectar Biosciences, Inc. is a US stock , located in Florham park of Nj and trading under the symbol CLRB

What is Cellectar Biosciences, Inc. stock quote today ?

Cellectar Biosciences, Inc. stock price is $1.54 today.

Is Cellectar Biosciences, Inc. stock public?

Yes, Cellectar Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap